The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain
| Status: | Recruiting |
|---|---|
| Conditions: | Angina |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 2/7/2015 |
| Start Date: | February 2011 |
| Contact: | Yehudith Assouline-Dayan, MD |
| Email: | yehudith-assouline-dayan@uiowa.edu |
| Phone: | 319-356-7209 |
Background: Noncardiac chest pain (NCCP) affects 200,000 new cases annually in USA. It is
associated with poor quality of life and high health care expenditure of 8 Billion Dollars a
year.
Gastroesophageal Reflux Disease(GERD), esophageal motility disorders, and psychological
issues may cause NCCP.
The mechanism(s) for pain continue to be explored and include central and peripheral
hypersensitivity, and mechanophysical abnormalities. Treatment of NCCP has focused on
relieving visceral hypersensitivity through pain modulators, such as tricyclics, trazodone,
or adenosine receptor antagonist, theophylline. Typically, only 40-50 % respond and clearly
there is a large unmet therapeutic need.
Cannabis is felt to be beneficial for vomiting, diarrhea and intestinal pain. The main
component of Cannabis acts through specific receptors, that are located primarily on central
and peripheral neurons (including the enteric nervous system) and myenteric plexus where
they modulate neurotransmitter release. Activation of these receptors reduces excitatory
enteric transmission and may improve esophageal hyperreactivity and hypersensitivity, the
hallmarks of NCCP.
STUDY PROTOCOL: The investigators will randomize 40 subjects with non-cardiac, non-reflux
chest pain to receive dronabinol (5 mg Bid), or placebo for 4 weeks. Chest pain symptoms and
esophageal sensorimotor properties will be assessed at baseline and at 4 weeks using symptom
diary and impedance planimetry. The primary outcome measure will be the frequency of chest
pain episodes. Secondary outcome measures include improvement in esophageal sensory
thresholds, reduced reactive contractions, frequency, amplitude, area under the curve, and
global improvement of symptoms.
HYPOTHESIS: Cannabinoids decrease esophageal hypersensitivity and ameliorate chest pain in
NCCP patients, when compared to placebo.
AIM: To perform a randomized double blind study to investigate the effects of Dronabinol, a
CB1 and CB2 agonist, in the treatment of patients with NCCP and examine its mechanism of
action.
associated with poor quality of life and high health care expenditure of 8 Billion Dollars a
year.
Gastroesophageal Reflux Disease(GERD), esophageal motility disorders, and psychological
issues may cause NCCP.
The mechanism(s) for pain continue to be explored and include central and peripheral
hypersensitivity, and mechanophysical abnormalities. Treatment of NCCP has focused on
relieving visceral hypersensitivity through pain modulators, such as tricyclics, trazodone,
or adenosine receptor antagonist, theophylline. Typically, only 40-50 % respond and clearly
there is a large unmet therapeutic need.
Cannabis is felt to be beneficial for vomiting, diarrhea and intestinal pain. The main
component of Cannabis acts through specific receptors, that are located primarily on central
and peripheral neurons (including the enteric nervous system) and myenteric plexus where
they modulate neurotransmitter release. Activation of these receptors reduces excitatory
enteric transmission and may improve esophageal hyperreactivity and hypersensitivity, the
hallmarks of NCCP.
STUDY PROTOCOL: The investigators will randomize 40 subjects with non-cardiac, non-reflux
chest pain to receive dronabinol (5 mg Bid), or placebo for 4 weeks. Chest pain symptoms and
esophageal sensorimotor properties will be assessed at baseline and at 4 weeks using symptom
diary and impedance planimetry. The primary outcome measure will be the frequency of chest
pain episodes. Secondary outcome measures include improvement in esophageal sensory
thresholds, reduced reactive contractions, frequency, amplitude, area under the curve, and
global improvement of symptoms.
HYPOTHESIS: Cannabinoids decrease esophageal hypersensitivity and ameliorate chest pain in
NCCP patients, when compared to placebo.
AIM: To perform a randomized double blind study to investigate the effects of Dronabinol, a
CB1 and CB2 agonist, in the treatment of patients with NCCP and examine its mechanism of
action.
Inclusion Criteria:
- Male or Female
- Ages 18-75 years
- Non-GERD related Non cardiac chest pain (Evaluated previously with an EGD, Esophageal
manometry, and 24 Hour ambulatory pH study)
- At least one episode of chest pain a week in the past month
- Previous negative cardiac evaluation (EKG ± Non invasive stress test ± Coronary
angiogram)
Exclusion Criteria:
- Subjects requiring narcotics or other pain medications
- Subjects with known esophagitis, Barrett's esophagus or peptic stricture on endoscopy
- Subjects with previous upper gastrointestinal surgery
- Pregnancy
- Subjects with Diabetes, neuromuscular disorders, or other severe co-morbidities
(Cardiovascular, respiratory, renal, hepatic, hematologic, endocrine, neurologic, and
psychiatric)
- Subjects with upper airway symptoms (such as hoarseness, wheezing or laryngospasm)
- Medications such as baclofen, H2 blockers, PPI, sucralfate and prokinetics.
- Known history of substance abuse
- Nursing mothers
We found this trial at
1
site
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
Click here to add this to my saved trials
